David Meyer, MD
Psychiatry · Paducah, KYNPI 1811957459
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (59.6%), food and beverage and education — rather than concentrated in one kind of arrangement. 21 manufacturers reported payments, led by Sunovion Pharmaceuticals Inc. at 38.9% of the total. Reporting peaked in 2019 at $6,818 and has fallen 86.5% since, to $921 in 2025. Among psychiatry clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 349 payments — averaging $48.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sunovion Pharmaceuticals Inc.$7K
- Otsuka America Pharmaceutical, Inc.$4K
- AbbVie$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Teva Pharmaceuticals USA, Inc.$672
- Axsome Therapeutics, Inc.$639
- plus $2K from 15 others
What the payments were for
- Speaking & faculty fees$10,06360%
- Travel & lodging$580%
- Food & beverage$6,68540%
- Education$760%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sunovion Pharmaceuticals Inc. | 21 | $6,571 |
| Otsuka America Pharmaceutical, Inc. | 14 | $4,281 |
| AbbVie(2 entities) | 86 | $1,382 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 55 | $1,052 |
| Teva Pharmaceuticals USA, Inc. | 25 | $672 |
| Axsome Therapeutics, Inc. | 36 | $639 |
| Tris Pharma Inc | 14 | $309 |
| Neurocrine Biosciences, Inc. | 5 | $287 |
| Vanda Pharmaceuticals Inc. | 7 | $266 |
| Supernus Pharmaceuticals, Inc. | 32 | $222 |
| Alkermes, Inc. | 11 | $218 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $194 |
| Lundbeck LLC | 10 | $167 |
| Johnson & Johnson | 5 | $155 |
| E.r. Squibb & Sons, L.L.C. | 2 | $134 |
| Idorsia Pharmaceuticals US Inc | 4 | $133 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $83 |
| Jazz Pharmaceuticals Inc. | 3 | $63 |
| Corium, LLC | 1 | $25 |
| Adlon Therapeutics L.p. | 1 | $14 |
| Shire North American Group Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LATUDA$6,122
- REXULTI$4,043
- CAPLYTA$220
- INGREZZA$213
- Austedo XR$213
- Fanapt$125
- Dyanavel XR$125
- Quillivant$125
- Quillichew ER$125
- UZEDY$120
- Auvelity$102
How this compares
$16,882 in reported general payments places this provider in the 95th percentile of 348 psychiatry providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 25 | $169,770 |
| VraylarCariprazine Hcl | 87 | $138,141 |
| IngrezzaValbenazine Tosylate | 12 | $94,313 |
| CaplytaLumateperone Tosylate | 28 | $53,510 |
| RexultiBrexpiprazole | 18 | $34,308 |
| Abilify MaintenaAripiprazole | 11 | $31,476 |
| AuvelityDextromethorphan Hbr/Bupropion | 21 | $22,293 |
| Aripiprazole | 192 | $21,118 |
| TrintellixVortioxetine Hydrobromide | 26 | $19,754 |
| LatudaLurasidone Hcl | 11 | $17,693 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 224 | $7,502 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 163 | $5,587 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 388 | $5,504 |
| Lurasidone Hcl | 45 | $5,462 |
| Quetiapine Fumarate | 248 | $4,276 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $672 | $169,77025 claims |
| AbbVieVraylar | $1,382 | $138,14187 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $287 | $94,31312 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $4,281 | $65,78429 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,052 | $53,51028 claims |
| Axsome Therapeutics, Inc.Auvelity | $639 | $22,29321 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $194 | $19,75426 claims |
| Sunovion Pharmaceuticals Inc.Latuda | $6,571 | $17,69311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 348 psychiatry providers in Kentucky.
Other psychiatry in Paducah
- Laurie BallewPaducah$3K
- Carmen PintoElizabethtown$1.7M
- Rifaat El-MallakhLouisville$1.6M
- Robert StewartLouisville$651K
- Mark WrightLexington$637K
- Carol MillerFrankfort$462K
- Ali FarooquiLouisville$393K
- Steven CroleyLexington$151K
- Joseph HarrisonOwensboro$131K
- Stephanie HallLouisville$106K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.